News and Announcements
Carl Zeiss Meditec AG Product Orders
- Published January 10, 2021 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Highlights:
• Receipt of orders from Carl Zeiss Meditec AG (CZM) for approx. A$350k
• Continued diversification of OptiScan Revenue Streams with receipts of A$570k from the balance of the payments for the 2 FIVE2 (ViewnVivo) sales to China based customers, the BioMedTech Horizons Program grant and from CZM in the December 2020 quarter.
Carl Zeiss Meditec AG Orders
OptiScan Imaging Limited (ASX: OIL) (‘the Company’ or ‘OptiScan’) is pleased to advise that it has received orders from Carl Zeiss Meditec AG pursuant to its Co-operation Agreement for approximately A$350k.
OptiScan’s CEO and Executive Chairman Darren Lurie, said:
“The orders from CZM represent the continuation of CZM’s commercial rollout of the CONVIVO® developed as part of the co-operation agreement between CZM and OptiScan.
We are also very pleased that OptiScan continues to diversify its revenue streams and cash flows. Receipts in the December 2020 quarter included $570k from the final payments for the 2 (two) FIVE2 (ViewnVivo) systems sold to China based customers, the BioMedTech Horizons Program grant to support the University of Melbourne’s Melbourne Dental School trial and payments from CZM. ”
About Optiscan Imaging Limited (ASX:OIL)
OptiScan (ASX:OIL) is an Australian listed company and a pioneer in the development and application of endomicroscopic imaging technologies for medical markets. Our multi-patented confocal imaging technology can be used for both cancer screening and tumour margin detection in cancer surgery. Our device enables real-time, in vivo imaging at the cellular level in clinical applications, providing a “digital” biopsy. The benefits of this “digital” biopsy include monitoring of early stage disease, earlier identification of pre-cancer and the potential to reduce the time doctors, patients and operating theatres are required to wait for pathology results, the number of repeat surgeries and actual biopsies required.
Optiscan has a collaboration with leading European medical technology company, Carl Zeiss Meditec AG and our technology is a critical part of the ZEISS CONVIVO™, that has brought OptiScan’s technology into the field of Neurosurgery. FDA 510(k) clearance and CE Mark have been obtained for the ZEISS CONVIVO™.
Company Updates
The Index Approach in Early-Stage Venture Capital: Reconsidered
The venture capital (VC) landscape is marked by its dynamism and complexity, especially in early-stage investing. The traditional approach in VC, characterised by a selective and intensive vetting process, often contrasts with the concept of ‘index investing.’ This article revisits the indexing approach in early-stage VC, incorporating insights from recent studies and data, including a […]
The Future Is Now: The Evolution of Dealflow with Wholesale Investor
If you’ve ever thought of investing or expanding your portfolio, there’s no better time than the present. In the fast-paced world of investment, things are changing at a breathtaking speed, and it’s crucial to stay ahead of the game. The Future of Deal Flow is Today Dealflow, the lifeblood of the investment world, is not […]
Investability of a Startup: A Comprehensive Guide for Angels and High-Net Worth Investors
Venturing into the Startup Scene Let’s dive into the intriguing world of startups. It’s a thrilling ride, isn’t it? Like finding a pearl in an ocean, spotting a promising startup amidst a sea of businesses is no easy task. This guide aims to light the way, focusing on the “The Investability of a Startup: 7 […]
Backed By Leading Investment Groups and Family Offices
